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Reply to Flamaing’s Letter
I was pleased to read the comments of Flamaing about the
need for a more ample vaccination approach, to better protect
the elderly population through influenza vaccination in various
population groups.
Enhancing vaccination rates in one of the largest portions of
the contagious population, i.e., children, is certainly a good idea
and, as reported by Flamaing, there is some evidence that in-
fluenza vaccine efficiency reduces flu in this population (1).
However, one cannot skip the gap and, to my knowledge, there
is only one study demonstrating the efficiency of flu vaccination
of children reducing flu incidence, death rates and medical con-
sumption among elderly population (2). The article cited by Fla-
maing concerns only the efficiency of flu vaccination in de-
creasing flu incidence in household adults and not in the elderly
population (2). In addition, there is no consensus ascertaining
that decreased flu rates in children will decrease flu rates in the
whole population (1). In addition, the main difference be-
tween Flamaing’s proposal and the theoretical benefits I pro-
posed in the manuscript is that, although there are only a few
of them, at least several studies have demonstrated the bene-
fits of HCW flu vaccination in reducing influenza-related death
in elderly persons living in nursing homes (3).
Also, it is a postulation to say that the decision of the
Committee on Immunization Practices in the US recom-
mending routine vaccination of children against influenza is
based on the effect of potential herd immunity in community-
dwelling populations. This may also first protect a special
group (children) who are indirectly responsible for the ab-
sence of working adults.
Lastly, if a broader strategy is needed to enhance vaccine
coverage in different target populations, we must be careful to
determine them appropriately, so that we are not put in the po-
sition, later, of having to cope with misunderstood messages by
the general population.
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Reply to Flamaing’s Letter
Dr. Flamaing’s comments on the various papers published in
Aging Clinical and Experimental Research on Vaccines in
Ageing European citizens (1-3) were very welcome, because
they stressed important and interesting points.
The need for “life course vaccine guidelines” was stressed by
Flamaing, who insisted on herd immunity, and we have absolutely
no doubt about its importance. To our knowledge, this was
the first time that the idea of “life course vaccine guidelines“ has
been proposed by geriatricians in the special issue of the journal.
Geriatricians can raise the concept, but they cannot lay down vac-
cination rules for children, even if it has been demonstrated in
Japan that influenza vaccination of children can decrease glob-
al excess deaths from pneumonia and influenza (4).
As stated clearly in the paper by Michel et al., geriatri-
cians and vaccine experts know that the immune response to
current vaccines is not optimal, considering the problem of im-
munosenescence. However, the proposal of vaccine guidelines
for the immunosenescent population will protect more indi-
viduals than in the past, while awaiting the production of new
vaccines, more suitable for this frail and often malnourished old
population (5).
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The debate concerning the use of pneumococcal polysac-
charide 23-valent vaccine (PPSV23) is an old one but it is currently
the only pneumococcal vaccine available for adults. The debate is
stimulated by the first trials of the not yet labelled 13-conjugated
pneumococcal vaccine for adults (6, 7). There is no doubt that the
PPSV23 vaccine is useful in adults and at-risk populations: Mer-
ck & Co. calculated the numbers needed to vaccinate based on a
variety of populations: a) for the over-65's, the number needed to
prevent an Invasive Pneumococcal Disease (IPD) case with a
10-year duration of protection was about 1200; b) when patients
with co-morbidities aged 18-64 are added, the number falls to 662
(8). Recent studies in older adults have examined the immuno-
logical responses among persons given either a polysaccharide vac-
cine or conjugate vaccine, followed by another dose of polysac-
charide or another dose of conjugate: a) the vaccine has a limit-
ed duration of protection (estimated at around 8 years); the per-
son’s risk increases with age; b) Dr. Flamaing was right when ar-
guing that the CDC recommended 1 dose of PPSV23 for most
people in a lifetime and 2 doses for certain people. However, c)
the overall generalization from recent studies is that it appears that,
if a polysaccharide vaccine is given before the conjugate vaccine,
the response to the conjugate is lower than with primary vacci-
nation; whereas, if the conjugate vaccine is given first, there
does not seem to be a decreased response with a subsequent dose
of either vaccine (7).
Another important point to be considered is that influenza in-
fection predisposes individuals to secondary bacterial pneumonia
(9). With the knowledge that, during the pre-antibiotic flu pan-
demics, IVP explained at least 20% of deaths (10), the need to
propose PPSV23 during the pre-pandemic phase was debated
in depth. Until now no formal answer was given on the economic
burden of the vaccine use. In any case this evaluation would take
into account the probable decrease of antibiotic prescription and
as a consequence the decrease of antibiotic resistance (11).
For all the above-mentioned arguments, I do not think
there is any need to modify the vaccination recommenda-
tions of the EUGMS-IAGG-ER.
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